Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 787-791

  Fleischer, Russell D ^a   Lok, Anna S F ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Clevudine; Mitochondrial toxicity; Pegylated interferon; Telbivudine

Indexed keywords

ADEFOVIR; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FIALURIDINE; INTERFERON; LAMIVUDINE; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; TELBIVUDINE; TENOFOVIR; VIDARABINE PHOSPHATE; ZIDOVUDINE;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIMB WEAKNESS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CREATINE KINASE; DRUG DISCOVERY; EARLY TERMINATION OF CLINICAL TRIALS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MITOCHONDRIAL MYOPATHIES; MUSCULAR DISEASES; NERVOUS SYSTEM DISEASES; NUCLEOSIDES; NUCLEOTIDES; PYRIMIDINONES; REPUBLIC OF KOREA;

EID: 69949126031     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.06.011     Document Type: Article

References (30)

1. Kim B.K., Oh J., Kwon B.K., Choe W.H., Ko S.Y., Rhee K.H., et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 51 (2009) 829-834
2. Seok J.I., Lee D.K., Lee C.H., Park M.S., Kim S.Y., Kim H.S., et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 49 (2009) 2080-2086
3. McKenzie R., Fried M.W., Sallie R., Conjeevaram H., Di Bisceglie A.M., Park Y., et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333 (1995) 1099-1105
4. Chu C.K., Boudinot F.D., Peek S.F., Hong J.H., Choi Y., Korba B.E., et al. Preclinical investigation of l-FMAU as an anti-hepatitis B virus agent. Antivir Ther 3 (1998) S113-S121
5. Lewis W., Day B.J., and Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2 (2003) 812-822
6. Wang J., and Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-beta-d-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother 40 (1996) 1555-1557
7. Tehrani O.S., Douglas K.A., Lawhorn-Crews J.M., and Shields A.F. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging 35 (2008) 1480-1488
8. Sun H., Sloan A., Mangner T.J., Vaishampayan U., Muzik O., Collins J.M., et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 32 (2005) 15-22
9. Bading J.R., Shahinian A.H., Bathija P., and Conti P.S. Pharmacokinetics of the thymidine analog 2′-fluoro-5-[(14)C]-methyl-1-beta-d-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells. Nucl Med Biol 27 (2000) 361-368
10. Colacino J.M., Malcolm S.K., and Jaskunas S.R. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother 38 (1994) 1997-2002
11. Cui L., Yoon S., Schinazi R.F., and Sommadossi J.P. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-d-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 95 (1995) 555-563
12. Lim S.G., Leung N., Hann H.W., Lau G.K., Trepo C., Mommeja-Marin H., et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 27 (2008) 1282-1292
13. Marcellin P., Mommeja-Marin H., Sacks S.L., Lau G.K., Sereni D., Bronowicki J.P., et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40 (2004) 140-148
14. Lim S.G., Krastev Z., Ng T.M., Mechkov G., Kotzev I.A., Chan S., et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 50 (2006) 1642-1648
15. Lee H.S., Chung Y.H., Lee K., Byun K.S., Paik S.W., Han J.Y., et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 43 (2006) 982-988
16. Yoo B.C., Kim J.H., Kim T.H., Koh K.C., Um S.H., Kim Y.S., et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 46 (2007) 1041-1048
17. Yoo B.C., Kim J.H., Chung Y.H., Lee K.S., Paik S.W., Ryu S.H., et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45 (2007) 1172-1178
18. Bowsher R.R., Compton J.A., Kirkwood J.A., Place G.D., Jones C.D., Mabry T.E., et al. Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrob Agents Chemother 38 (1994) 2134-2142
19. Richardson F.C., Engelhardt J.A., and Bowsher R.R. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci USA 91 (1994) 12003-12007
20. Lok A.S., Wilson L.A., and Thomas H.C. Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J Antimicrob Chemother 14 (1984) 93-99
21. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136 (2009) 486-495
22. Avila C, Laeufle R, Bao W. CK elevation during chronic hepatitis B (CHB) treatment with telbivudine: experience from the combined globe (NV-02B-007/CLDT600A2302) and NV-02B-015 (015) study clinical safety database. In: Poster #PE 140 presented at the 19th asian pacific association for the study of the liver (APASL); February 13-16, 2009, Hong Kong; 2009.
23. Goncalves J., Laeufle R., and Avila C. Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the novartis global database. J Hepatol 50 (2009) S329 Abstract #907
24. Weaver M, Wolf A, Persohn E, Grenet O, Pognan F, Dong M. Absence of Mitochondrial toxicity of telbuvidine in skeletal muscle cells, hepatocytes, and neuronal cells from rat or human. In: Abstract from the 19th asian pacific association for the study of the liver (APASL); February 13-16, 2009, Hong Kong; 2009.
25. Garcia G., Smith C.I., Weissberg J.I., Eisenberg M., Bissett J., Nair P.V., et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial. Ann Intern Med 107 (1987) 278-285
26. Yahagi K., Ueno Y., Mano Y., and Shimosegawa T. Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transpl 8 (2002) 1198-1199
27. Adani G.L., Baccarani U., Risaliti A., Bresadola F., Della Rocca G., and Viale P. Rhabdomyolysis due to lamivudine administration in a liver transplant recipient. Am J Transplant 5 (2005) 634
28. Marcellin P., Chang T., Lim S.G., Tong M., Sievert W., Schiffman M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
29. Nelson M.R., Katlama C., Montaner J.S., Cooper D.A., Gazzard B., Clotet B., et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21 (2007) 1273-1281
30. Hadziyannis S., Tassopoulos N., Heathcote E., Chang T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751